{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:02:26Z","timestamp":1763755346689,"version":"3.45.0"},"reference-count":15,"publisher":"Oncology Nursing Society (ONS)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2016,9,1]]},"DOI":"10.1188\/16.onf.544-547","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T14:50:21Z","timestamp":1471618221000},"page":"544-547","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer"],"prefix":"10.1188","volume":"43","author":[{"given":"Ximena","family":"DeCaire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Streu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Bergethon, K., Shaw, A.T., Ou, S., Katayama, R., Lovly, C.M., McDonald, N.T., . . . Iafrate, A.J. (2012). ROS1 rearrangements define a unique molecular class of lung cancers. Journal of Clinical Oncology, 30, 863\u2013870. doi:10.1200\/JCO.2011.35.6345","DOI":"10.1200\/JCO.2011.35.6345"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Camidge, D.R., Bang, Y.J., & Kwak, E. (2012). Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncology, 13, 1011\u20131019. doi:10.1016\/S1470-2045(12)70344-3","DOI":"10.1016\/S1470-2045(12)70344-3"},{"key":"3","unstructured":"Cao, B., Wei, P., Liu, Z., Bi, R., Lu, Y., Zhang, L., . . . Zhou, X. (2016). Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinocopathologic features. Journal of OncoTargets and Therapy, 9, 131\u2013138."},{"key":"4","unstructured":"Centers for Disease Control and Prevention. (2015). United States cancer statistics: Lung cancer. Retrieved from https:\/\/www\u2028.cdc.gov\/cancer\/lung\/statistics"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Chen, Y.F., Hsieh, M.S., Wu, S.G., Chang, Y.L., Shih, J.Y., Liu, Y.N., . . . Yang, P.C. (2014). Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. Journal of Thoracic Oncology, 9, 1171\u20131179. doi:10.1097\/JTO.0000000000000232","DOI":"10.1097\/JTO.0000000000000232"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Davies, K.D., Le, A.T., Theodoro, M.F., Skokan, M.C., Aisner, D.L., Berge, E.M., \u2028. . . Doebele, R.C. (2012). Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clinical Cancer Research, 18, 4570\u20134590. doi:10.1158\/1078-0432\u2028.CCR-12-0550","DOI":"10.1158\/1078-0432"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Devarakonda, S., Morgensztern, D., & Govidan, R. (2015). Genomic alterations in lung adenocarcinoma. Lancet, 16, 342\u2013351. doi:10.1016\/S1470-2045(15)00077-7","DOI":"10.1016\/S1470-2045(15)00077-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Mazieres, J., Zalcman, G., Crino L., Biondani, P., Barlesi, F., Filleron, T., . . . Gautschi, O. (2015). Crizotnib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort. Journal of Clinical Oncology, 33, 992\u20131001. doi:10.1200\/JCO.2014.58.3302","DOI":"10.1200\/JCO.2014.58.3302"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Sacher, A.G., Dahlberg, S.E., Heng, J., Mach, S., Janne, P.A., & Oxnard, G.R. (2016). Lung cancer diagnosis in the young is associated with enrichment for targetable genomic alterations and poor prognosis. JAMA Oncology, 2, 313\u2013320. doi:10.1001\/jamaoncol.2015.4482","DOI":"10.1001\/jamaoncol.2015.4482"},{"key":"10","unstructured":"Sechler, M., Cizmic, A.D., Avasarala, S., Van Scoyk, M., Brzezinski, C., Kelley, N., . . . Winn, R.A. (2013). Non-small-cell lung cancer: Molecular targeted therapy ad personalized medicine-drug resistance, mechanisms, and strategies. Pharmacogenomics and Personalized Medicine, 6, 25\u201335."},{"key":"11","unstructured":"Sequist L.V., & Neal, J.W. (2016) Personalized, genotype-directed therapy for advanced non-small cell lung cancer. Retrieved from http:\/\/bit.ly\/2aJRAMm"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Shan, L., Lian, F., Guo, L., Qiu, T., Ling, Y., Ying, J., & Lin, D. (2015). Detection of ROS1 gene rearrangement in lung adenocarcinoma: Comparison of IHC, FISH, and real-time RT PCR. PLOS One, 10, e0120422. doi:10.1371\/journal.pone.0120422","DOI":"10.1371\/journal.pone.0120422"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Shaw, A.T., Ou, S.H., Bang, Y.J., Camidge, D.R., Solomon, B.J., Salgia, R., . . . Iafrate, A.J. (2014). Crizotinib in ROS1-rearranged non-small cell lung cancer. New England Journal of Medicine, 371, 1963\u20131971. doi:10.1056\/NEJMoa1406766","DOI":"10.1056\/NEJMoa1406766"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Takeuchi, K., Soda, M., & Togashi, Y. (2012). RET, ROS1, and ALK fusions in lung cancer. Nature Medicine, 18, 378\u2013381. doi:10.1038\/nm.2658","DOI":"10.1038\/nm.2658"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Wu, S., Wang J., Zhou, L., Su, D., Liu, Y., Zhang, S., & Zeng, X. (2015). Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangement. Thoracic Cancer, 6, 413\u2013420. doi:10.1111\/1759-7714.12191","DOI":"10.1111\/1759-7714.12191"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/43\/5\/evolving-context-driver-mutations-ros1-rearrangement-metastatic-non-small-cell-lung-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:29Z","timestamp":1763754749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/43\/5\/evolving-context-driver-mutations-ros1-rearrangement-metastatic-non"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.onf.544-547","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"type":"print","value":"0190-535X"},{"type":"electronic","value":"1538-0688"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}